why choose us

First received: May 18, 2023

Clinical Trial: Ritlecitinib in CTCL

Study Status: Completed

Recruit Status: RECRUITING

Condition: CTCL

Study Type: INTERVENTIONAL


Official Title: A Single-center, Single-arm, Open-label Phase IIA Clinical Trial to Investigate Efficacy and Safety of Ritlecitinib (PF-06651600) in Patients With Cutaneous T Cell Lymphomas

Brief Summary: The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL).CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin.This study includes a 24 week Treatment Period and a 24 week Follow-up Period.This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin…

Read more